Please wait while we load the requested 10-K report or click the link below:
|||EPS of $1.06*, exceeding the Companys most recent outlook of $0.90 to $1.00;|
|||Revenue gains meeting or exceeding the Companys outlook in all three business segments; and|
|||Earnings before interest, taxes, depreciation and amortization (EBITDA) of $114 million* and free cash flow of $45 million*|
|*||A reconciliation of reported to adjusted results for the three months and years ended December 31, 2007 and 2006, is attached to this release.|
440 Route 22 East
Bridgewater, NJ 08807
The following information was filed by Alpharma Inc on Tuesday, February 26, 2008 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alpharma Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alpharma Inc.